Novo A/S Acquires Anti-Infectives Developer Xellia Pharmaceuticals from 3i
By Heather Cartwright
Pharma Deals Review: Vol 2013 Issue 6 (Table of Contents)
Published: 1 Jun-2013
DOI: 10.3833/pdr.v2013.i6.1946 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Novo A/S, the holding company of the Novo Group and a major shareholder in Novo Nordisk and Novozymes, has acquired the Norwegian anti-infectives developer Xellia Pharmaceuticals from the UK private equity group 3i and other current shareholders for approximately US$700 M...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS